Trials / Completed
CompletedNCT01861613
Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,040 (actual)
- Sponsor
- Hui Zhuang · Academic / Other
- Sex
- All
- Age
- 16 Years – 30 Years
- Healthy volunteers
- Accepted
Summary
At present, children less than 15 y of age have been regarded as a key group for hepatitis B immunization in China. However, there is not yet special immunization strategy for population above 15 y of age. In this study, we investigated the seroprevalence of hepatitis B and immune response to HB vaccine among Chinese college students to uncover the need on universal mass vaccination or booster immunization only for students with HBV vaccination history against hepatitis B in Chinese college students to inform decision making.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium) |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2011-11-01
- First posted
- 2013-05-23
- Last updated
- 2013-05-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01861613. Inclusion in this directory is not an endorsement.